The European Medicines Agency (EMEA) has recommended that Velcade (bortezomib) should not be used in patients with certain severe pulmonary or heart problems (acute diffuse infiltrative pulmonary and pericardial disease). Velcade is used to treat progressive multiple myeloma in patients who have failed to respond to at least one other treatment and who have already undergone or are unsuitable for bone marrow transplantation.
(more...)